Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
The company has confirmed that the deceased are 39
mRNA-1010 demonstrated superior relative vaccine efficacy
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Granules India receives 1 observation from USFDA for Chantilly facility
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated
